# Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05102149` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05102149](<https://clinicaltrials.gov/study/NCT05102149>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05102149

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 672 participants.

## Technical summary

Registry record NCT05102149. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2023-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 672 participants (planned count; ClinicalTrials.gov record NCT05102149, source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)
- Started: 2021-09-30 (actual) (ClinicalTrials.gov record NCT05102149, source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)
- Primary completion: 2023-11 (anticipated) (ClinicalTrials.gov record NCT05102149, source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)
- Completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT05102149, source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China; Taiwan (ClinicalTrials.gov record NCT05102149, source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05102149-2022-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): PB-201
- Intervention (Drug): Vildagliptin
- Intervention (Drug): PB-201 matched placebo
- Intervention (Drug): Vildagliptin matched placebo
- Lead sponsor: PegBio Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: PegBio Co., Ltd. (`cardio:org-pegbio-co-ltd`)

## Provenance

Content hash: 343aa89ab8dad17e4d5c2241bddda7e82f9fa47515255cb3426fecad81862415
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
